Analysis of follow-up results of chrono-chemotherapy or conventional chemotherapy combined with intensity modulated radiotherapy in locally advanced nasopharyngeal carcinoma
10.3760/cma.j.issn.0253-3766.2020.02.009
- VernacularTitle: 时辰化疗与常规化疗联合调强放疗治疗局部晚期鼻咽癌的随访结果分析
- Author:
Kuanqi LIU
1
;
Feng JIN
2
;
Hang JIANG
2
;
Weili WU
2
;
Yuanyuan LI
2
;
Jinhua LONG
2
;
Xiuling LUO
2
;
Xiuyun GONG
2
;
Xiaoxiao CHEN
2
;
Lina LIU
2
;
Jiaying GAN
3
;
Jianjiang ZHOU
4
Author Information
1. Department of Oncology, the Affiliated Cancer Hospital of Guizhou Medical University, Guiyang 550000, China
2. Department of Head and Neck Oncology, the Affiliated Cancer Hospital of Guizhou Medical University, Guiyang 550000, China
3. Department of Radiotherapy Technology, the Affiliated Cancer Hospital of Guizhou Medical University, Guiyang 550000, China
4. Laboratory of Molecular Biology, Guizhou Medical University, Guiyang 550001, China
- Publication Type:Clinical Trail
- Keywords:
Nasopharyngeal neoplasms;
Chrono-chemotherapy;
Intensity modulated radiotherapy;
Adverse event;
Survival
- From:
Chinese Journal of Oncology
2020;42(2):133-138
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the long-term effect and safety of chrono-chemotherapy combined with intensity modulated radiotherapy (IMRT) in locally advanced nasopharyngeal carcinoma (NPC).
Methods:160 patients with locally advanced NPC were randomly divided into a chrono group and conventional group according to random number table. In the first stage, all patients underwent two cycles of induced chemotherapy, consisting of docetaxel, cisplatin and 5-Fu every 21 days. Notably, patients received chrono-moduated chemotherapy according to circadian rhythm in the chrono group, and conventional chemotherapy in the conventional group. Then, 21 days after the completion of first stage, three cycles of concurrent cisplatin chemotherapy every 21 days were given to all patients during IMRT. The median follow-up after the completion of radiotherapy was 31 months. Long-term side effects and the survival of patients were observed.
Results:Patients in the chrono group had significantly lower rates of hearing loss (22.72%), dysphagia (0) and neck fibrosis (4.54%) compared with those in the conventional group (39.13%、8.69%, 15.94%, respectively, all P<0.05). Meanwhile, the 1- year overall survival rates (97.0% vs 92.8%), 3-year overall survival rates (80.3% vs 81.2%), 1-year progression free survival rates (95.5% vs 87.0%), 3-year progression free survival rates (71.2% vs 73.9%), 1-year locoregional relapse-free survival rates (97.0% vs 95.7%), 1-year locoregional relapse-free survival rates (92.4% vs 92.8%), 1-year distant metastasis-free survival rates (97.0% vs 98.6%) and 3-year distant metastasis-free survival rates (90.9% vs 91.3%) between the chrono group and the conventional group were not statistically significant (all P>0.05).
Conclusions:Compared with conventional chemotherapy, chrono-chemotherapy combined with IMRT didn′t affect long-term survival, but reducing the incidence of adverse events in patients with locally advanced NPC.
